BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10 - WLNS TV 6 Lansing - Jackson | Your Local News Leader

BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE BioLineRx Ltd.

JERUSALEM, Feb. 3, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present a company update at the BIO CEO & Investor Conference on Monday, February 10, 2014 at 2:30 p.m. EST.  The conference will be held at the Waldorf Astoria in New York.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

A live webcast of the presentation will be available on BioLineRx's website.  A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.

Investors or potential partners attending the conference, who wish to meet with Dr. Savitsky or Mr. Serlin, should contact the BIO Partnering Team at biopartnering@bio.org.

About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; BL-7010 for celiac disease, which is in the midst of a Phase 1/2 study; and BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in the first half of 2014.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Contact:

Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D.
jdrumm@tiberend.com 
+1-212-375-2664
Andrew Mielach
amielach@tiberend.com 
+1-212-375-2694

Or

Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipih@netvision.net.il

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WLNS. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.

Click Here to link to the FCC's public inspection file for WLNS-TV and Here to view the WLAJ-TV file. Persons with Disabilities who need assistance with issues relating to the content of this station's FCC public inspection file should contact: Teresa Morton- Program Director for WLNS and WLAJ at 517-372-8282. Questions or concerns relating to the accessibility of the FCC's public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or fccinfo@fcc.gov.